TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06647069: A Phase 1, Open-label, Multiple Ascending Dose Basket Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Select Autoimmune Rheumatic Diseases

Sponsor: Sanofi · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 62 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$4,082,040

Rescue Site Savings

+$2,697,900

Unlock Full NCT06647069 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06647069 Rescue Dossier →